Xencor
XNCR
24.26
-0.10
-0.41%
Xencor
US · XNCR
#2825 by market cap
Listed 1970
24.26
-0.10
-0.41%
Live - 5344 symbols - heartbeat 494s ago
· 2026-10-07 19:54
After-hours
24.26
0.00%
- Market cap
- 1.80B
- P/E (TTM)i
- -11.23
- P/Bi
- 3.58
- EPSi
- -1.24
- Div yieldi
- 0.00%
- 52W posi
- 69%
Reader sentiment
Are you bullish or bearish on XNCR?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 3.40, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +13.65% YoY
Margins
- Operating margin
- -141.35%
- Net margin
- -73.20%
Key ratios & quality
- Enterprise valuei
- 1.38B
- Altman Z-Scorei
- 3.40
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 40.60M | 156.70M | 122.69M | 275.11M | 164.58M | 174.62M | 110.49M | 125.58M |
| Gross profit | -- | -- | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 22.47M | 24.29M | 29.69M | 38.84M | 47.49M | 53.38M | 61.22M | 63.64M |
| Research & development | 97.50M | 118.59M | 169.80M | 192.51M | 199.56M | 253.60M | 227.69M | 239.43M |
| Operating profit | -79.37M | 13.82M | -76.80M | 43.77M | -82.47M | -132.36M | -178.41M | -177.50M |
| Pretax profit | -70.41M | 27.19M | -69.33M | 82.63M | -54.51M | -119.63M | -234.92M | -89.63M |
| Tax | 0 | 312.00K | 0 | 0 | 673.00K | 13.66M | 1.62M | 2.50M |
| Net profit | -70.41M | 26.88M | -69.33M | 82.63M | -55.18M | -133.30M | -236.54M | -92.14M |
| Basic EPS | -1 | 0 | -1 | 1 | -1 | -2 | -4 | -1 |
| Diluted EPS | -1.31 | 0.46 | -1.21 | 1.37 | -0.93 | -2.20 | -3.58 | -1.24 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 32.73M | 43.61M | 21.00M | 28.24M | 4.52M | 51.22M |
| Gross profit | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 17.34M | 15.12M | 14.15M | 17.04M | 17.71M | 16.38M |
| Research & development | 58.58M | 61.67M | 54.37M | 64.82M | 64.67M | 71.91M |
| Operating profit | -43.18M | -33.17M | -47.52M | -53.63M | -77.86M | -37.07M |
| Pretax profit | -48.27M | -31.08M | -6.03M | -4.27M | -128.64M | -21.92M |
| Tax | 367.00K | -250.00K | 0 | 2.39M | 280.00K | -190.00K |
| Net profit | -48.63M | -30.83M | -6.03M | -6.65M | -128.92M | -21.73M |
| Basic EPS | -1 | 0 | 0 | 0 | -2 | 0 |
| Diluted EPS | -0.66 | -0.41 | -0.08 | -0.09 | -1.71 | -0.29 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 315.73M | 558.41M | 637.67M | 424.37M | 675.34M | 635.60M | 577.60M | 599.82M |
| Cash & ST investments | 294.36M | 529.78M | 603.00M | 334.11M | 623.06M | 593.73M | 497.78M | 547.73M |
| Inventory | -- | -- | -- | -- | -- | -- | -- | -- |
| Total assets | 576.73M | 670.25M | 703.24M | 838.21M | 846.27M | 965.14M | 951.95M | 875.50M |
| Total current liabilities | 53.85M | 66.56M | 121.06M | 70.74M | 63.84M | 73.92M | 87.43M | 95.91M |
| Short-term debt | -- | 2.17M | 1.89M | -- | 4.71M | 31.15M | 51.46M | 46.53M |
| Long-term debt | -- | -- | -- | -- | -- | 161.77M | 115.16M | 76.48M |
| Total liabilities | 55,051,000.00 | 77,049,000.00 | 130,800,000.00 | 104,707,000.00 | 118,770,000.00 | 303,048,000.00 | 277,919,000.00 | 239,908,000.00 |
| Total equity | 521.68M | 593.20M | 572.44M | 733.50M | 727.50M | 662.09M | 674.03M | 635.59M |
| Retained earnings | -323.28M | -296.40M | -365.74M | -283.10M | -338.29M | -471.42M | -704.04M | -795.96M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 521.27M | 513.15M | 518.44M | 599.82M | 482.86M | 523.21M |
| Cash & ST investments | 469.57M | 443.86M | 471.04M | 547.73M | 444.95M | 456.45M |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | 904.69M | 879.42M | 868.81M | 875.50M | 736.85M | 724.96M |
| Total current liabilities | 88.44M | 96.08M | 86.49M | 95.91M | 73.46M | 81.87M |
| Short-term debt | 3.64M | 53.67M | 3.94M | 46.53M | 30.44M | 31.28M |
| Long-term debt | -- | 94.74M | -- | 76.48M | 82.12M | 77.54M |
| Total liabilities | 264,815,000.00 | 259,073,000.00 | 243,495,000.00 | 239,908,000.00 | 221,213,000.00 | 221,732,000.00 |
| Total equity | 639.87M | 620.35M | 625.32M | 635.59M | 515.63M | 503.23M |
| Retained earnings | -752.45M | -783.28M | -789.31M | -795.96M | -924.88M | -946.60M |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -79.76M | 64.37M | -5.00M | -16.85M | 24.49M | -77.93M | -202.19M | -135.12M |
| Depreciation & amortization | 3.25M | 4.30M | 5.79M | 7.49M | 8.80M | 11.50M | 12.11M | 10.51M |
| Free cash flow | -88.90M | 53.34M | -18.77M | -32.83M | -18.92M | -99.18M | -211.70M | -138.27M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 260.25M | 0 | 0 | 28.92M | 0 | 0 | 201.26M | 0 |
| Ending cash balance | 26.25M | 50.31M | 163.54M | 143.48M | 53.94M | 54.17M | 41.26M | 54.36M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -16.22M | -36.37M | -30.82M | -51.71M | -67.63M | -55.66M |
| Depreciation & amortization | 2.69M | 2.65M | 2.59M | 2.58M | 2.57M | 2.44M |
| Free cash flow | -17.66M | -36.75M | -31.00M | -52.85M | -68.24M | -56.20M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | -- | 0 | -- | -- |
| Ending cash balance | 39.96M | 44.73M | 28.58M | 54.36M | 14.36M | 44.85M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -17.52 | 4.82 | -11.90 | 12.65 | -7.55 | -18.06 | -34.55 | -14.00 |
| ROA %i | -14.56 | 4.31 | -10.10 | 10.72 | -6.55 | -14.02 | -24.43 | -10.06 |
| ROIC %i | -19.78 | 4.73 | -12.90 | 12.12 | -7.57 | -18.29 | -27.55 | -10.21 |
| 5-year avg ROE %i | -10.13 | -4.22 | -3.43 | -4.69 | -3.76 | -4.23 | -12.14 | -12.56 |
| EBIT margin %i | -173.37 | 8.82 | -62.59 | 15.91 | -50.11 | -82.36 | -179.45 | -45.95 |
| FCF / sales %i | -- | 34.04 | -- | -- | -- | 37.94 | -- | -- |
| Current ratioi | 5.86 | 8.39 | 5.27 | 6.00 | 10.58 | 8.60 | 6.61 | 6.25 |
| Quick ratioi | 5.67 | 8.29 | 5.18 | 5.66 | 10.21 | 8.35 | 6.39 | 6.02 |
| Debt / assetsi | 0.00 | 1.60 | 1.65 | 4.05 | 7.05 | 26.10 | 24.37 | 21.44 |
| LT debt / equityi | -- | 1.44 | 1.70 | 4.63 | 7.55 | 33.37 | 26.64 | 22.22 |
| Interest coveragei | -4,399.56 | -- | -- | -- | -- | -- | -5.41 | -1.81 |
| Revenue CAGR (3Y) %i | 13.51 | 12.86 | 38.53 | 89.23 | 1.65 | 12.48 | -26.22 | -8.62 |
| Net income CAGR (3Y) %i | -- | -15.86 | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -16.69 | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -33.15 | -28.88 | -19.39 | -14.00 | -29.84 | -29.07 |
| ROA %i | -23.21 | -20.06 | -14.12 | -10.06 | -21.01 | -20.36 |
| ROIC %i | -28.93 | -22.60 | -16.99 | -10.21 | -24.44 | -21.36 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -136.32 | -93.09 | -64.42 | -45.95 | -145.89 | -127.44 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 5.89 | 5.34 | 5.99 | 6.25 | 6.57 | 6.39 |
| Quick ratioi | 5.74 | 5.11 | 5.70 | 6.02 | 6.22 | 6.09 |
| Debt / assetsi | 7.50 | 24.22 | 7.97 | 21.44 | 23.77 | 23.46 |
| LT debt / equityi | 10.03 | 25.68 | 10.45 | 22.22 | 28.07 | 27.59 |
| Interest coveragei | -4.87 | -3.95 | -2.91 | -1.81 | -5.08 | -4.94 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Discovering and developing engineered antibody therapeutics to treat patients with cancer and100.00%
Quote time 2026-10-07 19:54:59 · For reference only, not investment advice and not tailored to your situation.